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Abstract
Background: Women with BRCA1 or BRCA2 mutations have a substantially increased risk of
breast and ovarian cancer compared with the general population. Therefore, prophylactic
mastectomy (PM) and bilateral salpingo-oophorectomy (BSO) have been proposed as risk-
reduction strategies for BRCA1/2  mutation carriers. We aimed to assess the feasibility of
coordinated PM and BSO in hereditary breast-ovarian cancer syndrome.
Methods: High risk women for breast and ovarian cancer who underwent coordinated PM and
BSO were included in this study. Clinical characteristics and surgical and oncologic outcomes were
retrospectively reviewed.
Results: Twelve patients underwent coordinated PM and BSO. Ten had history of previous breast
cancer. Autologous breast reconstruction was performed in ten patients. The mean age at surgery
was 43 (range 34–65). Mean operating time was 9.3 hours (range 3–16) with a mean postoperative
hospitalization of 5.4 days (range 4–8). Intraoperatively, there were no major surgical
complications. Postoperatively, one patient developed an abdominal wound dehiscence, another
reoperation for flap congestion; one had umbilical superficial epidermolysis, and one patient
developed aspiration pneumonia. At a mean follow-up of 84 months, 10 of patients were cancer-
free. Although no patients developed a new primary cancer, two developed a distant recurrence.
Conclusion: Coordinated PM and BSO is a feasible procedure with acceptable morbidity in
selected high-risk patients that desire to undergo surgery at one operative setting.
Background
Women with BRCA1 or BRCA2 mutation have a substan-
tially increased risk of breast and ovarian cancer com-
pared with the general population [1]. Breast cancer due
to a hereditary cause is about 5 to 10% of all malignant
breast disease and 25 to 40% of breast cancers that occur
in women younger than 35 years old. Cumulative lifetime
risk (to 70 years of age) for invasive breast cancer in
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women with BRCA1 and BRCA2 mutation is 40 to 85%
and for invasive epithelial ovarian cancer is 15 to 65% [1-
4]. Women who are BRCA1/2 mutation carriers also have
a 26–40% risk of contralateral breast cancer in 10 years
[5,6].
Currently, management strategies for high-risk women
include intense clinical follow up (every 3–6 months clin-
ical breast exams and annual breast magnetic resonance
imaging starting at 25 years of age, as well as gynecologic
cancer screening with twice-yearly transvaginal ultra-
sound and serum CA-125) [7] and chemoprevention with
tamoxifen [8,9]. A more aggressive risk reduction
approach is PM and BSO. Prophylactic surgery has been
shown to be very effective in significantly reducing breast
and ovarian cancer occurrence [10-12]. This report
describes the feasibility of coordinated PM and BSO in
women at high risk for breast-ovarian cancer.
Methods
Patient selection
Patients who underwent PM and BSO in the same opera-
tion were identified through search of databases main-
tained by the Department of Medical Informatics and the
Department of Gynecologic Oncology. This study was
approved by the University of Texas M. D. Anderson Can-
cer Center Institutional Review Board.
Surgical technique
The indications for PM and BSO, and other management
options were discussed with each patient. Risks, complica-
tions and alternatives were discussed and informed con-
sent was obtained. All patients underwent PM and BSO.
The patients who were evaluated and were felt to be good
candidates for autologous bilateral breast reconstruction
from the lower abdominal wall underwent bilateral flap
reconstruction of the breast using the transverse rectus
abdominus myocutaneous (TRAM) flaps or deep inferior
epigastric perforator (DIEP) flaps, and the prophylactic
surgeries simultaneously. Patients who did not undergo
breast reconstruction had their gynecologic procedure and
mastectomy at the same time.
Patients were administered general anesthesia. The breasts
and the abdomen were then prepared and draped in the
usual manner for exposure of the anterior chest and abdo-
men. Markings were made along the breast by the recon-
structive and breast surgery services. The breast surgical
oncology team performed the mastectomy while the
abdominal flaps were harvested and transferred by the
reconstructive team simultaneously. After that the
abdominal flap was inset into the recipient site and revas-
cularized if a free flap was performed. The flaps were tem-
porarily inset and secured to the chest wall while the
gynecologic oncology service performed the BSO. The
gynecologic team performed the BSO and in some cases,
also a total abdominal hysterectomy (TAH). The perito-
neum was closed by the gynecologic surgeons and at this
point the additional portion of the abdominal closure was
carefully performed by the reconstructive team.
Data Collection and Statistics
Medical records were retrospectively reviewed, and clini-
cal, demographic and genetic characteristics were
abstracted. Surgical procedures, operating times, compli-
cations and subsequent clinical follow up were also
recorded. For patients who had a personal history of pre-
vious breast cancer, we also collected data related to dis-
ease characteristics and follow up. The results are
described as average, standard deviation and percentage.
Results
From June 1996 to July 2003, twelve high-risk women
had coordinated PM and BSO. The mean age at prophy-
lactic surgery was 43 years (range 34–65). The clinical
characteristics of the patients are described in Table 1.
Eleven of the patients had undergone BRCA testing and
were known to have a deleterious mutation. Ten patients
had a personal history of breast cancer prior to the pro-
phylactic surgery. Nine patients received chemotherapy,
and six received radiation therapy.
Table 1: Clinical Characteristics (n = 12)
Characteristics Number (%)
Mean age at prophylactic surgery (range) 43 (34–65)
BMI (SD) 22.7 ± 3.1*
Race
White, Non-Ashkenazie Jewish 10 (83.3)
Ashkenazie Jewish 1 (8.3)
Hispanic 1 (8.3)
Personal previous history of breast cancer 10 (83.3)
Primary 9 (75)
Primary with local recurrence 1 (8.3)
Personal history of ovarian cancer 0 (0)
Family history of breast cancer 11 (91.6)
First degree relatives with breast cancer 9 (75)
Family history of ovarian cancer 2 (16.6)
First degree relatives with ovarian cancer 1 (8.3)
Smoking 2 (16.66)
Parity
1 live birth 2 (16.66)
2 live birth 7 (58.33)




Due to chemotherapy 1 (8.33)
Due to use of tamoxifen 1 (8.33)
Due to previous hysterectomy 2 (16.66)
Natural menopause 1 (8.33)
*Values are presented as average ± standard deviationBMC Cancer 2008, 8:101 http://www.biomedcentral.com/1471-2407/8/101
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During the prophylactic surgeries, breast and gynecologic
surgeries were performed at the same operation. Six
patients underwent contralateral mastectomy, four thera-
peutic/completion mastectomies in addition to the pro-
phylactic contralateral mastectomies and two underwent
bilateral prophylactic mastectomy. All patients underwent
open BSO and seven also underwent a total abdominal
hysterectomy (TAH). Ten patients underwent bilateral
reconstruction, nine with TRAM flap and one with DIEP
flap. The indication and technical details of the coordi-
nated surgical prophylactic and complementary proce-
dures are detailed in Table 2.
The mean operating time was 9.3 hours (range 3 – 16)
with a hospital stay of 5.4 days (range 4–8). There were no
cases of death, bleeding requiring blood transfusion or
other major complication during surgery.
The postoperative complications seen are listed in the
Table 2. In one patient a large ventral hernia was found
during the TRAM flap dissection, which was repaired with
polyproprolene mesh at that time. Postoperatively, this
patient had an abdominal wound dehiscence. The
abdominal wall (fascia and mesh) remained intact. The
wound was managed conservatively and completely
closed about 1 month later with no further complications.
A patient who underwent reconstruction with pedicle
TRAM flaps, right delayed, left immediate had a reopera-
tion for left flap congestion. A super-charge of left pedicle
TRAM flap, artery and vein, was successfully performed.
Placement with bilateral saline-filled mammary implants
was performed one year later due to a contour deformity
of the superior pole of the breast mound. Another patient
who had prophylactic contralateral mastectomy and TAH-
BSO followed by reconstruction of both breasts with bilat-
eral free TRAM flap, had some superficial epidermolysis of
her umbilicus postoperatively. This was managed con-
servatively, leaving a hypertrophic scar with no further
complications. The development of aspiration pneumo-
nia was seen postoperatively in one patient who under-
went contralateral prophylactic mastectomy, TAH-BSO,
and free TRAM reconstruction. This was treated aggres-
sively with pulmonary physiotherapy and intravenous
antibiotics. Otherwise, the postoperative course was une-
ventful. Even with those complications, all patients recov-
ered well postoperatively. There were no complications
directly attributable to the combination of the gyneco-
logic and breast procedures.
At a mean follow-up was 84 months, none of the patients
developed a new breast cancer. However, two patients
died due to breast cancer metastasis; both patients had a
breast cancer diagnosis at the time of their risk-reducing
surgery. The first patient was diagnosed with breast cancer
at 29 years of age with a clinical stage IIIA breast cancer.
She underwent prophylactic contralateral mastectomy
and BSO one year after the diagnosis. She was free of dis-
ease for 2 years when was found to have bone, lung and
brain metastasis. She received palliative chemotherapy
but died from breast cancer nine months later. The second
Table 2: Coordinated Surgical Procedures and Complications
Patient Previous Breast Cancer Prophylactic Breast Surgery Prophylactic Gynecologic 
Surgery
Reconstruction Postoperative Complications
1 yes Contralateral mastectomy BSO (previous TAH) Free TRAM None
2 no Bilateral mastectomy TAH-BSO Pedicle TRAM None
3 yes Contralateral mastectomy BSO (previous TAH) no None
4 yes Contralateral mastectomy TAH-BSO no None
5 yes Contralateral mastectomy BSO Pedicle TRAM Reoperation for flap 
congestion
6 yes Contralateral mastectomy TAH-BSO Free TRAM Superficial epidermolysis of 
the umbilicus
7 yes Contralateral + Completion 
mastectomy
TAH-BSO Free TRAM None
8 yes Contralateral mastectomy BSO Free DIEP None
9 no Bilateral mastectomy TAH-BSO Free TRAM None
10 yes Contralateral mastectomy TAH-BSO Free TRAM Postoperative aspiration 
pneumonia
11 yes Contralateral + Completion 
mastectomy
BSO (previous TAH) Free TRAM None
12 yes Contralateral + Completion 
mastectomy
TAH-BSO Free TRAM Abdominal wound dehiscence
BSO = Bilateral salpingo-oophorectomy.
TAH = Total abdominal hysterectomy.
TRAM = Transverse rectus abdominus myocutaneous.
DIEP = Deep inferior epigastric perforator.BMC Cancer 2008, 8:101 http://www.biomedcentral.com/1471-2407/8/101
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one was 31 when was diagnosed with a Stage IIA breast
cancer. She underwent prophylactic contralateral mastec-
tomy and BSO about 2 years after the diagnosis. Ten
months after prophylactic surgery, she was found to have
metastatic disease to the brain. She received palliative
chemotherapy and deceased four and a half years later.
Both patients had undergone a negative staging work-up
with a chest x-ray, bone scan and abdominal CT at their
initial breast cancer diagnosis (11 and 15 months prior to
prophylactic surgery). The remaining 10 patients did not
have recurrence and are still alive.
Discussion
Several studies have shown that the risk of breast and
ovarian cancer can be decreased by prophylactic surgery in
carriers of BRCA mutations. Prophylactic BSO not only
reduces the risk of ovarian cancer by 80–95% but also
reduces the risk of contralateral breast cancer by 50%
[10,13]. Rebbeck et al demonstrated that bilateral PM
reduced the risk of breast cancer by 90% in women with
intact ovaries and by 95% in women who underwent both
PM and oophorectomy [12]. Our study aimed to evaluate
the feasibility of coordinated prophylactic mastectomy
and BSO in high risk breast-ovarian cancer women.
Women with breast cancer who carry deleterious BRCA
mutations are at increased risk of developing a second pri-
mary breast cancer as well as a primary ovarian cancer
[14]. However, the prevention of a second primary breast
cancer by prophylactic mastectomy may be overshadowed
by the prognosis of the first tumor. In a decision analysis,
Schrag et al demonstrated that life expectancy gains from
risk-reducing surgery is greatest for patients that are
young, for high-penetrance mutations, and in node-nega-
tive disease [15]. The breast cancer-related deaths of two
of the patients in our small series underscore the chal-
lenges of patient selection for risk-reducing procedures.
It is critical to discuss immediate breast reconstruction
with all patients undergoing PM. Most patients undergo-
ing bilateral PM for risk-reduction are candidates for
reconstruction. Immediate reconstruction is also usually
feasible in most patients undergoing a mastectomy for
breast cancer, but may be deferred in patients in whom
postmastectomy radiation therapy is planned [16,17]
Reconstructive options include implant-based reconstruc-
tion, as well as autologous reconstruction approaches
such as pedicled TRAM flap, or free TRAM flap with vari-
ous degrees of muscle sparing, the deep inferior epigastric
artery perforator (DIEP) and the superficial inferior epi-
gastric artery (SIEA) flap. Implant-based reconstruction is
preferred by some due to ease of performance, while
autologous tissue reconstruction is preferred by others
due to its natural shape, soft consistency and long-lasting
aesthetic results. The choice of reconstruction is an impor-
tant determinant of operative time, and potential morbid-
ity of the surgery. Most patients who elect contralateral
prophylactic mastectomy (CPM) at our institution
undergo autologous tissue reconstruction [18]. The choice
of reconstruction is an important determinant of opera-
tive time, and potential morbidity of the surgery. At our
institution, with the use of free TRAM flap reconstruction,
flap complications have been observed in 24% of
patients, and donor site complications in 15% of patients
[19]. In this series, 10 of 12 patients underwent recon-
struction with abdominal TRAM flaps, and even though
the reconstruction increased the operative time, there
were no major intraoperative or postoperative complica-
tions. The complications seen in this study are in line with
our previous institutional experience with mastectomy
and breast reconstruction [19]. Thus in this limited series,
adding the gynecologic surgery to the breast procedure
resulted in acceptable morbidity.
Although we did not have any substantial complications
associated with the gynecologic surgery in our series, there
is a potential risk in adding the gynecologic procedure to
prophylactic surgery, especially in the setting of autolo-
gous reconstructive surgery. There is a small risk of intra-
abdominal bleeding, which could lead to a low flow state
for the autologous flap, and in the case of a microvascular
free flap, even to flap loss. Hysterectomy exposes the
abdomen to vaginal bacterial flora and may also increase
the risk of wound infections and other wound complica-
tions, a risk factor for infection and loss of tissue-
expander/implant-based reconstruction. The magnitude
of a bilateral autologous breast reconstruction is signifi-
cant for both patient and surgeon, and the impact of flap
loss, while rare (less than 2% in our institution), is pro-
found. For gynecologic procedures, the patient is placed
in Trendelenberg immediately after revascularization of
the flap, the most vulnerable time period for vascular
compromise. In addition, the flap can not be easily visu-
alized at this time. There are accordant risks for flap avul-
sion or compromise of the vascular pedicle, especially in
the newer perforator based flaps, such as the DIEP flap,
which were developed to spare the abdominal donor site
morbidity associated with increased muscle harvest of the
rectus abdominis muscle, but leave the vascular pedicle
much less protected. Additionally, there is need for careful
closure of the abdominal donor site to prevent risk of her-
niation.
Coordinated single operation has three main advantages.
The first is that it allows for a single operation and recov-
ery, potentially enhancing patient convenience. The sec-
ond is that oophorectomy may allow for the initiation of
aromatase inhibitors for endocrine treatment in premen-
opausal patients with estrogen-receptor positive disease.
The third is that it allows for early ovarian risk reduction,BMC Cancer 2008, 8:101 http://www.biomedcentral.com/1471-2407/8/101
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minimizing the theoretical risk of ovarian cancer develop-
ment in between staged procedures. These advantages of a
single operation should be weighed against potential
morbidity of adding the gynecological surgery to the pro-
phylactic mastectomy with reconstruction. As an alterna-
tive,
As breast reconstruction is a staged procedure involving a
series of 2–3 procedures several months apart, the gyneco-
logic procedure may be performed during one of the sec-
ondary reconstructive procedures.
In our series of patients, seven of nine patients who had a
uterus at that time also underwent TAH during the proce-
dure. No complications due to hysterectomy were seen.
However, our group and others are moving away from
performing hysterectomy routinely in these patients. In
patients with uterine or cervical abnormalities, hysterec-
tomy may be considered. In addition, women who have
taken tamoxifen may consider hysterectomy due to the
increased risk of endometrial cancer. However, patients
need to be counseled that the addition of hysterectomy to
bilateral oophorectomy may increase surgical time and
morbidity [20].
Our study is limited as it is a small retrospective case series
from a single institution. Further, our center has signifi-
cant expertise in breast and gynecologic oncology as well
as reconstructive surgery; this coordinated approach may
be met with additional challenges, including higher rates
of morbidity, when performed by lower volume surgical
teams. Finally, due to our short clinical follow-up and
small sample size, we are unable to report long-term risk
reduction rates.
Conclusion
In conclusion, our study showed that coordinated PM and
BSO is a feasible procedure with acceptable morbidity for
patients at high risk for breast and ovarian cancer who
elect to undergo synchronous risk-reduction operations.
However, the optimal approach and timing for risk-reduc-
ing surgery in women at high-risk for breast-ovarian can-
cer needs to be determined in a multidisciplinary fashion,
taking into account several factors including the time-line
of greatest breast and gynecologic cancer risk and also the
potential complications of the operations.
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